Russell Barton
Chief Operating Officer at ACUMEN PHARMACEUTICALS, INC.
Net worth: 392 311 $ as of 2024-03-30
Profile
Russell Barton is currently the Director of Clinical Operations at AgeneBio, Inc., the Chief Operating Officer at Acumen Pharmaceuticals, Inc., and the President & Consultant at Pharma Sagacity Consulting LLC.
He previously worked as the Chief Operating Officer at Eli Lilly & Co. Barton received his undergraduate degree from Illinois State University and his graduate degree from Purdue University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-01-17 | 96,867 ( 0.16% ) | 392 311 $ | 2024-03-30 |
Russell Barton active positions
Companies | Position | Start |
---|---|---|
ACUMEN PHARMACEUTICALS, INC. | Chief Operating Officer | 2019-03-31 |
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Chief Tech/Sci/R&D Officer | 2019-09-30 |
Pharma Sagacity Consulting LLC | President | 2017-12-31 |
Former positions of Russell Barton
Companies | Position | End |
---|---|---|
ELI LILLY AND COMPANY | Chief Operating Officer | - |
Training of Russell Barton
Illinois State University | Undergraduate Degree |
Purdue University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
ACUMEN PHARMACEUTICALS, INC. | Health Technology |
Private companies | 2 |
---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
Pharma Sagacity Consulting LLC |
- Stock Market
- Insiders
- Russell Barton